
Cartesian Therapeutics, Inc.
- Jurisdiction
United States - LEI
529900NMN0LACZOL7C43 - ISIN
US8162123025 (RNAC )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
Profile
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€883.95K - Gross margin
100.0% - EBIT
-€75.82M - EBIT margin
-8,577.6% - Net income
-€31.24M - Net margin
-3,534.1%
Statement period: - (published )
Dividends
No dividend payouts